Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma

Figure 2 Ultrasound and contrast-enhanced ultrasound of the liver at diagnosis, six months after the beginning of treatment, five months after lenalidomide interruption, and six months after lenalidomide reintroduction. A: Multiple lesions visualized in the arterial phase (arrows); B: Stable disease (arrow); C: Target lesion is increased (32.9 mm now vs 22.8 mm previously) (arrow); D: Target lesion is slightly decreased in size again (28.1 mm) (arrow).